PDX1
Basic information
Region (hg38): 13:27920000-27926313
Previous symbols: [ "IPF1" ]
Links
Phenotypes
GenCC
Source:
- maturity-onset diabetes of the young type 4 (Strong), mode of inheritance: AR
- permanent neonatal diabetes mellitus (Strong), mode of inheritance: AR
- pancreatic agenesis 1 (Strong), mode of inheritance: AR
- maturity-onset diabetes of the young type 4 (Definitive), mode of inheritance: AD
- pancreatic agenesis 1 (Moderate), mode of inheritance: AR
- pancreatic agenesis (Supportive), mode of inheritance: AR
- maturity-onset diabetes of the young (Supportive), mode of inheritance: AD
- permanent neonatal diabetes mellitus (Supportive), mode of inheritance: AD
- maturity-onset diabetes of the young type 4 (Strong), mode of inheritance: AD
- pancreatic agenesis 1 (Strong), mode of inheritance: AR
- monogenic diabetes (Moderate), mode of inheritance: AD
- pancreatic agenesis 1 (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Pancreatic agenesis 1; Neonatal diabetes mellitus | AR | Endocrine; Gastrointestinal | Individuals may manifest in infancy with findings including intrauterine growth retardation, postnatal growth deficiency, and signs of diabetes mellitus (eg, hyperglycemia, glycosuria), as well as severe dehydration, and recognition can allow preventive measures related to potential sequelae, surveillance (eg, with blood glucose monitoring as well as surveillance for other common sequelae of diabetes mellitus affecting systems such as the renal and ophthalmogic systems); In the case of an acute diabetic crisis, rapid treatment (eg, with rehydration and IV insulin, transitioning to SQ insulin when stable) is indicated, though rapid-acting and (non-continuous) short-acting insulin preparations may result in severe hypoglycemia in young patients; Due to exocrine (as well as endocrine) pancreatic insufficiency, some individuals may benefit from enzymatic replacement | Biochemical; Endocrine; Gastrointestinal; Neurologic | 8506821; 8988180; 9326926; 9399911; 9649577; 10545531; 10545530; 10720084; 11575290; 11935326; 12970316; 19496967; 20009086; 20301620; 20546293; 20621032; 21521318; 21937992; 22124438; 23320570; 25087164 |
ClinVar
This is a list of variants' phenotypes submitted to
- Maturity-onset diabetes of the young type 4;Pancreatic agenesis 1 (1 variants)
- Permanent neonatal diabetes mellitus (1 variants)
- Pancreatic agenesis 1 (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PDX1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 37 | 42 | ||||
missense | 59 | 66 | ||||
nonsense | 3 | |||||
start loss | 0 | |||||
frameshift | 8 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 13 | |||||
Total | 1 | 10 | 73 | 42 | 7 |
Variants in PDX1
This is a list of pathogenic ClinVar variants found in the PDX1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
13-27920029-AG-A | Benign (Nov 18, 2020) | |||
13-27920053-G-T | Likely benign (Sep 04, 2018) | |||
13-27920088-ACTCCCGG-A | not specified | Likely benign (Feb 01, 2018) | ||
13-27920088-A-ACTCCCGG | Maturity-onset diabetes of the young type 4 | Uncertain significance (Aug 18, 2011) | ||
13-27920103-CTCCCGGCTCCCGGT-C | PDX1-related disorder | Uncertain significance (Dec 07, 2023) | ||
13-27920114-C-T | PDX1-related disorder | Likely benign (Jul 28, 2023) | ||
13-27920121-C-T | Maturity-onset diabetes of the young type 4 • not specified | Conflicting classifications of pathogenicity (Mar 25, 2021) | ||
13-27920144-C-T | Maturity onset diabetes mellitus in young | Benign/Likely benign (Jan 01, 2024) | ||
13-27920146-G-C | Pancreatic hypoplasia • Type 2 diabetes mellitus;Maturity-onset diabetes of the young type 4;Pancreatic agenesis 1 • not specified | Uncertain significance (Jun 25, 2023) | ||
13-27920166-G-A | not specified • Monogenic diabetes • Maturity-onset diabetes of the young type 4 • Maturity onset diabetes mellitus in young | Uncertain significance (Oct 25, 2022) | ||
13-27920185-A-T | Uncertain significance (Apr 17, 2021) | |||
13-27920190-T-C | Type 2 diabetes mellitus • Type 2 diabetes mellitus;Maturity-onset diabetes of the young type 4;Pancreatic agenesis 1 • Diabetes mellitus type 2, susceptibility to | Uncertain significance (Nov 07, 2023) | ||
13-27920195-G-C | Likely benign (Aug 29, 2022) | |||
13-27920200-A-T | Uncertain significance (Jan 05, 2023) | |||
13-27920215-C-T | Pancreatic hypoplasia | Uncertain significance (-) | ||
13-27920220-T-G | Pancreatic hypoplasia | Uncertain risk allele (-) | ||
13-27920230-G-A | Uncertain significance (May 17, 2022) | |||
13-27920235-C-A | not specified • Maturity-onset diabetes of the young type 4 • Monogenic diabetes • Type 2 diabetes mellitus • Maturity onset diabetes mellitus in young | Conflicting classifications of pathogenicity (Aug 28, 2024) | ||
13-27920235-C-G | not specified • Type 2 diabetes mellitus;Maturity-onset diabetes of the young type 4 | Conflicting classifications of pathogenicity (Sep 19, 2023) | ||
13-27920235-C-T | not specified | Uncertain significance (Aug 30, 2023) | ||
13-27920236-C-A | Maturity-onset diabetes of the young type 4;Pancreatic agenesis 1;Type 2 diabetes mellitus | Uncertain significance (Sep 20, 2023) | ||
13-27920237-T-C | Likely benign (Jun 23, 2018) | |||
13-27920239-C-T | not specified | Uncertain significance (Feb 13, 2023) | ||
13-27920240-G-A | Uncertain significance (Jul 08, 2022) | |||
13-27920245-T-G | Maturity-onset diabetes of the young type 4;Type 2 diabetes mellitus | Uncertain significance (Aug 16, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PDX1 | protein_coding | protein_coding | ENST00000381033 | 2 | 6212 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0178 | 0.901 | 125549 | 0 | 8 | 125557 | 0.0000319 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.266 | 167 | 158 | 1.06 | 0.00000714 | 1757 |
Missense in Polyphen | 41 | 49.592 | 0.82674 | 561 | ||
Synonymous | -2.81 | 106 | 75.0 | 1.41 | 0.00000360 | 615 |
Loss of Function | 1.47 | 4 | 8.69 | 0.460 | 3.71e-7 | 95 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000716 | 0.0000617 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000552 | 0.0000529 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000343 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Activates insulin, somatostatin, glucokinase, islet amyloid polypeptide and glucose transporter type 2 gene transcription. Particularly involved in glucose-dependent regulation of insulin gene transcription. As part of a PDX1:PBX1b:MEIS2b complex in pancreatic acinar cells is involved in the transcriptional activation of the ELA1 enhancer; the complex binds to the enhancer B element and cooperates with the transcription factor 1 complex (PTF1) bound to the enhancer A element. Binds preferentially the DNA motif 5'-[CT]TAAT[TG]-3'. During development, specifies the early pancreatic epithelium, permitting its proliferation, branching and subsequent differentiation. At adult stage, required for maintaining the hormone-producing phenotype of the beta-cell.;
- Disease
- DISEASE: Pancreatic agenesis 1 (PAGEN1) [MIM:260370]: A disease characterized by isolated hypoplasia or agenesis of the pancreas, pancreatic beta-cell failure resulting in neonatal insulin- dependent diabetes mellitus, and exocrine pancreatic insufficiency. {ECO:0000269|PubMed:8988180}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Diabetes mellitus, non-insulin-dependent (NIDDM) [MIM:125853]: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; DISEASE: Maturity-onset diabetes of the young 4 (MODY4) [MIM:606392]: A form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease. {ECO:0000269|PubMed:9326926}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Type II diabetes mellitus - Homo sapiens (human);Maturity onset diabetes of the young - Homo sapiens (human);Insulin secretion - Homo sapiens (human);Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics;Type II diabetes mellitus;PTF1A related regulatory pathway;FOXA2 and FOXA3 transcription factor networks
(Consensus)
Recessive Scores
- pRec
- 0.603
Haploinsufficiency Scores
- pHI
- 0.187
- hipred
- Y
- hipred_score
- 0.697
- ghis
- 0.438
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.683
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Pdx1
- Phenotype
- muscle phenotype; cellular phenotype; homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; digestive/alimentary phenotype; renal/urinary system phenotype; immune system phenotype; liver/biliary system phenotype;
Zebrafish Information Network
- Gene name
- pdx1
- Affected structure
- acinar cell
- Phenotype tag
- abnormal
- Phenotype quality
- decreased amount
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;liver development;type B pancreatic cell differentiation;glucose metabolic process;generation of precursor metabolites and energy;transcription by RNA polymerase II;nitric oxide mediated signal transduction;positive regulation of cell population proliferation;negative regulation of cell population proliferation;animal organ morphogenesis;morphogenesis of embryonic epithelium;insulin secretion;exocrine pancreas development;endocrine pancreas development;positive regulation of insulin secretion involved in cellular response to glucose stimulus;glucose homeostasis;positive regulation of transcription by RNA polymerase II;digestive tract development;detection of glucose;negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway;negative regulation of type B pancreatic cell apoptotic process
- Cellular component
- nucleus;nucleoplasm;cytosol;nuclear speck
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;chromatin binding;DNA-binding transcription factor activity